Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $43.00.

Several research firms have commented on LYEL. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Citizens Jmp reissued a “market outperform” rating and set a $34.00 target price on shares of Lyell Immunopharma in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th.

Lyell Immunopharma Trading Up 5.5%

LYEL opened at $12.63 on Wednesday. The stock’s fifty day simple moving average is $17.84 and its 200 day simple moving average is $22.75. Lyell Immunopharma has a 1-year low of $8.46 and a 1-year high of $45.00. The stock has a market cap of $294.66 million, a PE ratio of -0.92 and a beta of -0.09.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting the consensus estimate of ($1.10). The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. Equities analysts forecast that Lyell Immunopharma will post -7.87 earnings per share for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BBR Partners LLC bought a new stake in Lyell Immunopharma during the fourth quarter valued at $210,000. ExodusPoint Capital Management LP bought a new stake in Lyell Immunopharma in the fourth quarter valued at $262,000. Marshall Wace LLP acquired a new position in shares of Lyell Immunopharma during the second quarter valued at about $94,000. Jane Street Group LLC acquired a new stake in Lyell Immunopharma in the fourth quarter valued at approximately $382,000. Finally, Barclays PLC grew its position in Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock valued at $491,000 after purchasing an additional 14,775 shares during the period. 66.05% of the stock is owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.